Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
May 01 2023 - 7:30AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, announced today it was granted a new U.S. Patent
No. 11,622,955 entitled “SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD
PRESSURE THERAPY,” from the United States Patent and Trademark
Office (USPTO), expanding Anavex’s coverage of treatment methods
for ANAVEX®2-73 (blarcamesine), to the treatment of systolic
hypertension, or lowering systolic blood pressure.
“We are extremely pleased with the expansion of
the patent portfolio for ANAVEX®2-73 (blarcamesine) for the
indication of hypertension which affects nearly half (47%) of
adults in the United States, especially since elevated systolic
blood pressure is a major health economy problem within our aging
society,” said Christopher U. Missling, PhD, President and Chief
Executive Officer of Anavex. “This new patent will add to our
already robust patent portfolio relating to ANAVEX®2-73, and
further demonstrate our strong overall commitment to protecting the
full range of commercial opportunities of our product
portfolio.”
Anavex’s newest patent will be expected to
remain in force at least until November 2038, not including any
patent term extensions. The new patent expands existing protections
for the use of ANAVEX®2-73 in treating neurodegenerative disorders
to the new use for treating systolic hypertension in addition to
existing antihypertension therapy. The market for uncontrolled
hypertension is 37 million adults in the U.S. alone.
About Hypertension (High blood pressure)
The global antihypertensive drugs market size
was worth around USD 20.5 billion in 2021 and is predicted to grow
to around USD 39.5 billion by 2030.1 Systolic hypertension is a
major health economy problem within our aging society. Elevated
systolic blood pressure is even more associated with cardiovascular
morbidity and mortality than diastolic blood pressure.2 According
to the U.S. Centers for Disease Control, nearly half (47%) of
adults in the United States have hypertension, defined as a
systolic blood pressure greater than 130 mmHg or a diastolic blood
pressure greater than 80 mmHg, or are taking medication for
hypertension. In 2020, more than 670,000 deaths in the United
States had hypertension as a primary or contributing cause. Only
about 1 in 4 adults (24%) with hypertension have their condition
under control. About half of adults (45%) with uncontrolled
hypertension have a blood pressure of 140/90 mmHg or higher. This
includes 37 million U.S. adults. About 34 million adults who are
recommended to take medication may need it to be prescribed and to
start taking it. High blood pressure costs the United States about
USD 131 billion each year.3
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of novel therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders, including
Alzheimer's disease, Parkinson's disease, Rett syndrome, and other
central nervous system (CNS) diseases, pain, and various types of
cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine),
has successfully completed a Phase 2a and recently a Phase 2b/3
clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept
study in Parkinson's disease dementia, and both a Phase 2 and a
Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is
an orally available drug candidate that restores cellular
homeostasis by targeting sigma-1 and muscarinic receptors.
Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer's disease. ANAVEX®2-73 also
exhibited anticonvulsant, anti-amnesic, neuroprotective, and
anti-depressant properties in animal models, indicating its
potential to treat additional CNS disorders, including epilepsy.
The Michael J. Fox Foundation for Parkinson's Research previously
awarded Anavex a research grant, which fully funded a preclinical
study to develop ANAVEX®2-73 for the treatment of Parkinson's
disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic
receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid, and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors:Andrew J.
BarwickiInvestor RelationsTel: 516-662-9461Email:
andrew@barwicki.com
1 https://www.fnfresearch.com/antihypertensive-drugs-market2
Duprez D. Treatment of isolated systolic hypertension in the
elderly. Expert Rev Cardiovasc Ther. 2012 Nov;10(11):1367-73. doi:
10.1586/erc.12.117. PMID: 232443573
https://www.cdc.gov/bloodpressure/facts.htm
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Oct 2023 to Oct 2024